GTXi (GTXI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GTXi (GTXI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	7/28/2008 1:03:51 PM
	of 85

GTx clinical trial cleared by safety board Memphis Business Journal Monday, July 28, 2008 - 10:47 AM CDT GTx Inc. will continue its Phase III clinical trial of prostate cancer drug toremifene after the trial cleared a planned safety review by an independent board. The Data Safety Monitoring Board reviewed safety data of the nearly 3,000 patients enrolled in the trials. The DSMB meets every six months to review the data. The trials are studying the effect of the 20-milligram dosage of toremifene in men with high-grade prostatic intraepithelial neoplasia, a condition seen in men before they develop prostate cancer. GTx officials are hoping their trials will show toremifene reduces the incidence of prostate cancer in these patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next